EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...

To keep up with COPD research and care developments, the 2026 Global Initiative for Chronic Obstructive Lung Disease report ...

Chronic obstructive pulmonary disease (COPD) is a multi-faceted disease that is a major cause of morbidity and mortality worldwide, and is a significant burden in terms of healthcare resource ...

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Mucolytic agents decrease mucus viscoelastic properties, improve mucociliary clearance and decrease sputum production and appear designed to provide symptomatic relief to mucus hypersecretion in COPD.

Chronic obstructive pulmonary disease – COPD for short – is one of the most common diseases of the lung. It affects almost 300 million people worldwide, of which about three million die every year. A ...

REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory ...

Erdosteine is an original mucoactive molecule, synthesized and developed by Edmond Pharma, and registered in many countries worldwide. There is evidence, both in preclinical and clinical studies, that ...

EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...